drugset / Trial / NCT05380323

A Study of LY3541105 in Healthy and Overweight Participants

NCT05380323 ↗

Phase 1 Completed 206 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3541105 in healthy and overweight participants. Blood tests will be performed to check how much LY3541105 gets into the bloodstream and how long it takes the body to eliminate it. The study will also evaluate the effects of LY3541105 on body weight and assess safety and tolerability of LY3541105. This is a 3-part study and may last up to 15, 26 and 24 weeks for each participant and may include up to 7, 15 and 16 visits in parts A, B and C, respectively.

Timeline

Start
2022-05-10
Primary completion
2024-08-27
Completion
2024-08-27

Drugs

EvaluationDrugModalityDoseRoute
Subject COLULINTIDE Protein / enzyme biologic — Subcutaneous

Indications